Non-invasive glioblastoma immunoprofiling by printed peptide arrays. Mock, A. & Herold-Mende, C. OncoImmunology, 5(2):e1069941, February, 2016. Number: 2
Non-invasive glioblastoma immunoprofiling by printed peptide arrays [link]Paper  doi  abstract   bibtex   
Immune monitoring assays for patient stratification and treatment efficacy in clinical trials are in demand. We have recently described a cost-effective non-invasive assay to determine the immune status of glioblastoma patients. Profiling antitumor serum antibodies by customized printed peptide arrays identified response against a tenascin-C (TNC) peptide as a robust prognostic biomarker.
@article{mock_non-invasive_2016,
	title = {Non-invasive glioblastoma immunoprofiling by printed peptide arrays},
	volume = {5},
	issn = {2162-402X},
	url = {https://www.tandfonline.com/doi/full/10.1080/2162402X.2015.1069941},
	doi = {10.1080/2162402X.2015.1069941},
	abstract = {Immune monitoring assays for patient stratification and treatment efficacy in clinical trials are in demand. We have recently described a cost-effective non-invasive assay to determine the immune status of glioblastoma patients. Profiling antitumor serum antibodies by customized printed peptide arrays identified response against a tenascin-C (TNC) peptide as a robust prognostic biomarker.},
	language = {en},
	number = {2},
	urldate = {2019-11-28},
	journal = {OncoImmunology},
	author = {Mock, Andreas and Herold-Mende, Christel},
	month = feb,
	year = {2016},
	note = {Number: 2},
	keywords = {Accessories, Application - Antibody Validation / Epitope Mapping, Application - Biomarker Discovery, Application - Cancer Research, Country - Germany, Human, PEPperCHIP - Customized - Linear, Sample Type - Plasma, Sample Type - Serum},
	pages = {e1069941},
}

Downloads: 0